Roche Holding AG (RHHBY)
| Market Cap | 366.65B +53.0% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | 20.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 22.57 |
| Forward PE | 17.52 |
| Dividend | 0.87 (1.53%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 6,159,862 |
| Average Volume | 3,066,435 |
| Open | 56.90 |
| Previous Close | 57.12 |
| Day's Range | 56.74 - 57.98 |
| 52-Week Range | 34.75 - 58.40 |
| Beta | 0.17 |
| RSI | 68.16 |
| Earnings Date | Jan 29, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Roche's (RHHBY) Fenebrutinib Shows Promise in Phase 3 MS Trial
Roche's (RHHBY) Fenebrutinib Shows Promise in Phase 3 MS Trial
Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial
Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in patients with primary progressive multiple sclerosi...
Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in red...
Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc...
Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Basel, 07 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK) inhibi...
Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the...
These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys?
Weight loss candidates from Amgen and Roche performed well in phase 2 studies. These could be exciting additions to these companies' drug portfolios.
ClearBridge International Growth ADR Strategy exits Linde, adds Roche in Q4 2025
ClearBridge International Growth ADR Strategy underperformed its primary MSCI EAFE benchmark for the fourth quarter of 2025, and slightly underperformed its secondary MSCI EAFE Growth benchmark.
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability...
Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
Roche Holding AG 2025 Q4 - Results - Earnings Call Presentation
2026-01-29. The following slide deck was published by Roche Holding AG in conjunction with their 2025 Q4 earnings call.
Roche Holding AG (RHHBF) (FY 2025) Earnings Call Highlights: Strong Pharma Growth and Strategic ...
Roche Holding AG (RHHBF) (FY 2025) Earnings Call Highlights: Strong Pharma Growth and Strategic Investments Drive Profit Surge
Full Year 2025 Roche Holding AG Earnings Call Transcript
Full Year 2025 Roche Holding AG Earnings Call Transcript
Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case
Hoffman-La Roche aka Roche Holding AG delivered robust 2025 results, with core EPS up 11% CER and a resilient pharma division driving growth. RHHBY's pipeline, especially in obesity and cardiovascular...
Roche Sees Steady 2026 Growth As Key Drugs Post Double-Digit Gains
Roche Holdings AG (OTC: RHHBY) reported fiscal 2025 sales of 61.5 billion Swiss Francs (around $76.96 billion), up 7% (+2% in CHF) due to strong demand for pharmaceutical products and diagnostic solu...
How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity
Roche hopes to rival Eli Lilly and Novo Nordisk in the red-hot weight-loss space. The Swiss drug giant is working on four key drugs.
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock. As pharma companies face a "patent cliff" where existing drugs lose exclusivity, th...
Roche (RHHBY) Faces Currency Challenges Despite Sales Growth
Roche (RHHBY) Faces Currency Challenges Despite Sales Growth
Roche's annual results hit by currency headwinds
Roche's U.S drug prices will be lowered, says CEO
Thomas Schinecker, CEO of Roche discusses the company's weight loss medication pipeline, and explains how the company's pharmaceutical pricing deal with the U.S. administration will impact their finan...
Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline
The Swiss drugmaker said it expects sales to grow in the mid-single-digit range, with core EPS growth in the high-single-digit range at constant currencies.
Roche FY25 Results Climb, Lifts Dividend; Sees Growth In FY26
(RTTNews) - Swiss drug major Roche Holding AG (RHHBY) reported Thursday higher profit and sales in fiscal 2025, mainly with growth in Pharmaceuticals Division sales. The company also announced higher ...
Roche (RHHBY) Reports Strong FY Results and Positive Outlook
Roche (RHHBY) Reports Strong FY Results and Positive Outlook
Roche Holding Non-GAAP EPS of CHF 19.46, revenue of CHF 61.52B; issues FY26 outlook
Roche sees high single-digit earnings growth in 2026
Roche ROG.S said on Thursday it expects 2026 group sales to grow in the mid single-digit percentage range, while targeting core earnings per share growth in the high single-digit range.